181 related articles for article (PubMed ID: 8335014)
1. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.
Kanra G; Ceyhan M; Vandevoorde D; Bogaerts H
Eur J Pediatr; 1993 Jun; 152(6):478-83. PubMed ID: 8335014
[TBL] [Abstract][Full Text] [Related]
2. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
[TBL] [Abstract][Full Text] [Related]
3. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine.
Vanura H; Just M; Ambrosch F; Berger RM; Bogaerts H; Wynen J; Vandevoorde D; Wiedermann G
Vaccine; 1994; 12(3):210-4. PubMed ID: 8165852
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana.
Afari EA; Kamiya Y; Nkrumah FK; Dunyo SK; Akpedonu P; Kamiya H; Fukai F
Ann Trop Paediatr; 1996 Mar; 16(1):39-48. PubMed ID: 8787364
[TBL] [Abstract][Full Text] [Related]
5. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine.
Kosuwon P; Warachit B; Hutagalung Y; Borkird T; Kosalaraksa P; Bock HL; Poovorawan Y
Vaccine; 2003 Oct; 21(27-30):4194-200. PubMed ID: 14505898
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
[TBL] [Abstract][Full Text] [Related]
8. Comparative trial to assess the reactogenicity of the diphtheria-tetanus-acellular pertussis (DTPa) vaccine plus Haemophilus influenzae type B (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine plus Hib conjugate vaccine, administered in single injection a.
Calbo F; Dal-Ré R; Díez-Delgado J; Oña S; Sánchez-Prados F; García-Corbeira P;
Med Clin (Barc); 2002 Jan; 118(1):1-4. PubMed ID: 11803003
[TBL] [Abstract][Full Text] [Related]
9. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
12. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
[TBL] [Abstract][Full Text] [Related]
13. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
[TBL] [Abstract][Full Text] [Related]
14. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children.
Pichichero ME; Badgett JT; Rodgers GC; McLinn S; Trevino-Scatterday B; Nelson JD
Pediatr Infect Dis J; 1987 Apr; 6(4):352-63. PubMed ID: 3495775
[TBL] [Abstract][Full Text] [Related]
15. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R
Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
Chan SH; Tan PT; Han HH; Bock HL
Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
[TBL] [Abstract][Full Text] [Related]
19. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.
Vandermeulen C; Theeten H; Rathi N; Kuriyakose S; Han HH; Sokal E; Hoppenbrouwers K; Van Damme P
Vaccine; 2015 Jun; 33(26):3026-34. PubMed ID: 25613716
[TBL] [Abstract][Full Text] [Related]
20. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.
Sänger R; Behre U; Krause KH; Loch HP; Soemantri P; Herrmann D; Schmitz-Hauss E; Wolter J; Hoet B
Eur J Pediatr; 2007 Dec; 166(12):1229-36. PubMed ID: 17235521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
